Lupin Share Price in Focus After USFDA Grants Final Approval for Pitolisant Tablets 4.45 mg and 17.8 mg as Bioequivalent to Wakix on 17 August 2026
- August 17, 2026
- Posted by: Neeraj Pandey
- Category: Market
Lupin share price Rs 2,228.60 (-0.29%). USFDA final approval for Pitolisant Tablets 4.45mg and 17.8mg. Bioequivalent to Wakix. High Rs 2,243.50 (52W high). Vol 21,615 vs avg 86,200 (-74.92%).
Quick Answer
Lupin share price is in focus on 17 August 2026 after the company received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths, approved as bioequivalent to Wakix. The USFDA approval gives Lupin entry into the narcolepsy treatment generic market in the United States.
The Lupin share price received a significant regulatory milestone on 17 August 2026: the US Food and Drug Administration has granted final approval for Lupin’s Abbreviated New Drug Application for Pitolisant Tablets in two strengths, 4.45 mg and 17.8 mg. The tablets have been approved as bioequivalent to Wakix, the branded narcolepsy treatment made by Harmony Biosciences. This USFDA approval gives Lupin entry into the US generic narcolepsy market, a segment where Wakix has been growing strongly.
The Lupin share price reaction is interesting: the stock touched a new 52-week high of Rs 2,243.50 intraday before pulling back to Rs 2,228.60, a mild decline of 0.29 percent. This price action reflects the pattern common to ANDA approvals: the initial regulatory approval triggers a push to new highs as the news is absorbed, but the limited trading volume (21,615 shares versus the five-day average of 86,200, a 74.92 percent decline) means the move is happening in a thin post-holiday session. The Lupin share price’s 52-week high touch today is technically significant regardless of the mild price decline from that peak.
Click Here – Get Free Investment Predictions
| Lupin Share Price Data | Value |
|---|---|
| CMP (17 Aug 2026) | Rs 2,228.60 (-0.29% / -Rs 6.40) |
| Intraday High (= 52-Week High) | Rs 2,243.50 |
| Intraday Low | Rs 2,219.75 |
| USFDA Approval | Final ANDA approval for Pitolisant Tablets |
| Dosage Strengths | 4.45 mg and 17.8 mg |
| Reference Brand | Wakix (by Harmony Biosciences) |
| Indication | Narcolepsy treatment |
| Volume Today | 21,615 shares |
| 5-Day Avg Volume | 86,200 shares |
| Volume vs Avg | -74.92% |
Lupin share price: What the Pitolisant ANDA Means
Pitolisant is a histamine H3 receptor inverse agonist approved for the treatment of excessive daytime sleepiness in adults with narcolepsy. Wakix (brand name) was the first drug in this class approved by the USFDA and has been a commercial success for Harmony Biosciences. Lupin’s ANDA approval as a bioequivalent to Wakix means its generic version can be substituted for the branded drug in the US market, potentially at a significantly lower price point.
For the Lupin share price, the Pitolisant ANDA is part of Lupin’s broader US generics business, which is one of the company’s key revenue drivers. The narcolepsy market is relatively niche compared to cardiovascular or diabetes generics, but Pitolisant’s growing adoption for daytime sleepiness treatment and Wakix’s significant branded revenues make this a valuable ANDA. Each additional US ANDA approval diversifies the Lupin share price’s revenue base and reduces reliance on any single product or therapeutic area.
Track Lupin Share Price and Pharma Sector Data on Univest Screener
Download the Univest iOS App or Univest Android App to monitor Lupin share price and pharma regulatory approvals from Univest.
Conclusion
The Lupin share price touched a 52-week high of Rs 2,243.50 intraday on 17 August 2026 following USFDA final approval for Pitolisant Tablets 4.45 mg and 17.8 mg as bioequivalent to Wakix. The stock is currently at Rs 2,228.60, down 0.29 percent on thin post-holiday volume. The ANDA approval gives Lupin entry into the US narcolepsy generic market. Consult a SEBI-registered financial advisor before making investment decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Lupin share price news today?
Ans. The Lupin share price is in focus after USFDA granted final approval for Lupin’s Pitolisant Tablets in 4.45 mg and 17.8 mg strengths as bioequivalent to Wakix. The Lupin share price touched a new 52-week high of Rs 2,243.50 intraday before settling at Rs 2,228.60, down 0.29 percent.
What is Pitolisant and why is its USFDA approval significant for the Lupin share price?
Ans. Pitolisant is a histamine H3 receptor inverse agonist approved for narcolepsy treatment. Wakix is its brand name made by Harmony Biosciences. Lupin’s USFDA-approved generic Pitolisant Tablets can now be substituted for Wakix in the US market at a lower price, giving the Lupin share price a new US revenue stream in the narcolepsy therapy area.
Why has the Lupin share price touched a 52-week high today?
Ans. The Lupin share price touched a new 52-week high of Rs 2,243.50 intraday because USFDA ANDA approvals are material positive events for pharmaceutical companies — they provide new revenue opportunities in the US generics market. However, the thin post-holiday volume (21,615 shares versus the 86,200 average) meant the The stock high couldn’t be sustained and the stock is now down slightly at Rs 2,228.60.
What is an ANDA and how does it affect the Lupin stock?
Ans. An ANDA (Abbreviated New Drug Application) is the regulatory pathway for generic drug approvals by the USFDA. When USFDA approves an ANDA, the generic manufacturer can market a drug that is bioequivalent to the branded reference product at a lower price. For the The pharma stock, each ANDA approval adds to Lupin’s US generics revenue base and diversifies its product portfolio.
What is Wakix and who makes it?
Ans. Wakix (pitolisant) is a branded narcolepsy treatment made by Harmony Biosciences Holdings in the United States. It was the first histamine H3 receptor inverse agonist approved by the USFDA for narcolepsy. Lupin’s ANDA approval as bioequivalent to Wakix allows it to market the generic version of this drug in the US.
Why is the The company’s shares trading on thin volume today?
Ans. The This pharmaceutical stock volume of 21,615 shares is 74.92 percent below the five-day average of 86,200. Today is the first trading session after India’s Independence Day long weekend, and many institutional participants are not yet fully back in the market, resulting in the thin The stock volume despite the positive USFDA approval news.
Where can I track the Lupin stock live?
Ans. The The pharma stock can be tracked on NSE (ticker: LUPIN) and BSE websites. USFDA approval announcements are disclosed by the company through exchange filings under corporate announcements. The Univest Screener provides live The company’s shares data alongside pharma sector peer comparison.
